Indication
as monotherapy for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2144
Pharmaceutical company
MSD
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Advice due date:
13 May 2019
SMC meeting date:
02 April 2019
Patient group submission deadline:
04 February 2019